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Letter to Editor
Leiomyomas are the most common benign smooth muscle 
uterine neoplasm of the reproductive age group.[1] They are 
steroid-dependent tumors. Leiomyomas are diagnosed by 
clinical examination, ultrasonography, and histopathology 
examination of hysterectomy specimens or excised myomas.[2] 
Biomarkers are biological compounds that can be obtained 
from serum or other easily accessible tissues. They are 
the reflection of physiology or pathology.[3] Biomarkers 
which are raised in leiomyoma are prolactin, serum total 
protein, S. HLA-G, VEGF, Ghrelin, lactate dehydrogense A, 
hypermethylated death-associated protein kinase, CA-125, 
hematopoietic growth factors, human epididymis protein 4, 
proteomics, and gonadal hormones.
Prolactin is a protein hormone involved in various mammalian 
physiologic actions such as lactogenesis. It is also expressed 
in other tissues including uterine leiomyomas.[4] It is raised 
in uterine leiomyomas.
Serum protein is lower in patients with leiomyoma probably 
because these patients are predisposed to abnormal uterine 
bleed and menorrhagia.[2]
S human leukocyte antigen G (HLA-G) is an antigen of the 
immune system which is also expressed in uterus. It is 
elevated in melanoma, ovarian, and breast carcinoma. Basta 
et al.[5] demonstrated higher levels of HLA-G in patients with 
leiomyoma.
Vascular endothelial growth factor (VEGF) and hematopoietic 
growth factor – VEGF is an angiogenic peptide for the growth 
of tumors. Chen et al.[6] evaluated raised serum VEGF in 
women with uterine leiomyoma. Similarly, hematopoietic 
growth factor, such as macrophage colony stimulating 
factor (M-CSF) and granulocyte colony stimulating (G-CSF), 
are raised in endometrial carcinomas and leiomyomas.
Ghrelin – It is secreted by the stomach. Markowska[7] found 
raised levels of ghrelin in women with leiomyoma.
Lactate dehydrogenase A – It is involved in anerobic 
glycolysis, and its levels are raised in ovarian cancers and 
leiomyoma.[8]
CA-125 is raised in ovarian carcinoma as well as in patients 
with endometrial carcinoma and other benign gynecological 
diseases such as endometriosis, pelvic inflammatory diseases, 
adenomyosis, and uterine leiomyomas.[9]
Growth hormones – leiomyomas need hormonal milieu 
for their growth and maintenance as evident by molecular 
studies that leiomyoma exhibits more estrogen receptors 
than normal myometrium.[2]
Conclusion
Biomarkers in leiomyoma are useful for diagnosis as well as 
for prognosis. There are a number of markers that are raised 
in leiomyoma uteri, however, ideally it should be sensitive, 
specific, and cost effective.
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